Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
16
datasets available to search
ShareScore release 0.9.0
Dataset results
16 results for “Volumetric modulated arc therapy”
Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases
ClinicalTrials.gov study NCT02220491. IPD Sharing: Not stated. Countries: 1. Publications: 20.
Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases
ClinicalTrials.gov study NCT01046123. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis
ClinicalTrials.gov study NCT06984523. IPD Sharing: YES. Countries: 1. Publications: 0.
Volumetric Intensity Modulated Arc Therapy vs. Conventional Radiotherapy for Cancer Pain
ClinicalTrials.gov study NCT03374592. IPD Sharing: NO. Countries: 0. Publications: 2.
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
ClinicalTrials.gov study NCT03384199. IPD Sharing: YES. Countries: 1. Publications: 0.
Accelerated Partial Breast Irradiation Using External Beam Volumetric Modulated Arc Therapy (VMAT): a Randomised Non-inferiority Trial of 30 Gy Versus 26 Gy in Five Fractions Investigating Patient-rep
ClinicalTrials.gov study NCT06909032. IPD Sharing: NO. Countries: 1. Publications: 0.
Dataset related to article "Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience."
<p>INTRODUCTION:</p> <p>We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) after lung-sparing surgery with pleurectomy and decortication.</p> <p>MATERIALS AND METHODS:</p> <p>Patients affected by MPM who had undergone pleurectomy and decortication and adjuvant radiotherapy with VMAT were included. The endpoints of the present analysis were local control, progression-free survival, and overall survival. Assessment of the variables affecting survival was performed using univariate and multivariate Cox proportional hazard models.</p> <p>RESULTS:</p> <p>A total of 49 patients were included in the present study. Of the 49 patients, 96% had been treated with a trimodality approach. Radiotherapy was delivered to a median dose of 44 Gy in 22 fractions (range, 22-59.4 Gy). The treatment was well tolerated, with just 2 grade 3 acute toxicities, 1 grade 5, and 2 grade 4 toxicities recorded during the follow-up period. The median follow-up period was 27.4 months. The local control rate at 12, 24, and 36 months was 75.2%, 67.4%, and 56.5%, respectively. The median progression-free survival was 14.9 months (95% confidence interval [CI], 7.5-25.2). The median overall survival was 21.5 months (95% CI, 15.3-37.1). On multivariate analysis, the administration of carboplatin- instead of cisplatin-based chemotherapy (hazard ratio, 2.97; 95% CI, 1.22-7.26; P = .017) and R2 resection (hazard ratio, 1.95; 95% CI, 1.27-2.99; P = .002) showed a negative correlation with overall survival. On univariate analysis, the percentage of the heart receiving >20 Gy and >30 was associated with the occurrence of late pneumonitis (P = .018 and P = .077).</p> <p>CONCLUSION:</p> <p>VMAT is feasible in the setting of MPM after lung-sparing surgery. The toxicity rates were reduced with this technique compared with historical data of older techniques. Local and distant failure remain a major issue to be addressed in future trials.</p>
Dataset related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"
<p>This record contains data related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"</p> <p>Abstract</p> <p><strong>Background: </strong> To investigate the role of intensity modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT) for advanced supradiaphragmatic Hodgkin's lymphoma (HL) in young female patients by assessing dosimetric features and modelling the risk of treatment related complications and radiation-induced secondary malignancies.</p> <p><strong>Methods: </strong> A group of 20 cases (planned according to the involved-site approach) were retrospectively investigated in a comparative planning study. Intensity modulated proton plans (IMPT) were compared to VMAT RapidArc plans (RA). Estimates of toxicity were derived from normal tissue complication probability (NTCP) calculations with either the Lyman or the Poisson models for a number of endpoints. Estimates of the risk of secondary cancer induction were determined for lungs, breasts, esophagus and thyroid. A simple model-based selection strategy was considered as a feasibility proof for the individualized selection of patients suitable for proton therapy.</p> <p><strong>Results: </strong> IMPT and VMAT plans resulted equivalent in terms of target dose distributions, both were capable to ensure high coverage and homogeneity. In terms of conformality, IMPT resulted ~ 10% better than RA plans. Concerning organs at risk, IMPT data presented a systematic improvement (highly significant) over RA for all organs, particularly in the dose range up to 20Gy. This lead to a composite average reduction of NTCP of 2.90 ± 2.24 and a reduction of 0.26 ± 0.22 in the relative risk of cardiac failures. The excess absolute risk per 10,000 patients-years of secondary cancer induction was reduced, with IMPT, of 9.1 ± 3.2, 7.2 ± 3.7 for breast and lung compared to RA. The gain in EAR for thyroid and esophagus was lower than 1. Depending on the arbitrary thresholds applied, the selection rate for proton treatment would have ranged from 5 to 75%.</p> <p><strong>Conclusion: </strong> In relation to young female patients with advanced supradiaphragmatic HL, IMPT can in general offer improved dose-volume sparing of organs at risk leading to an anticipated lower risk of early or late treatment related toxicities. This would reflect also in significantly lower risk of secondary malignancies induction compared to advanced photon based techniques. Depending on the selection thresholds and with all the limits of a non-validated and very basic model, it can be anticipated that a significant fraction of patients might be suitable for proton treatments if all the risk factors would be accounted for.</p> <p> </p>
Dataset related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"
<p>This record contains raw data related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"</p> <p><strong>Abstract</strong></p> <p><strong>Purpose</strong>: Total marrow (and lymphoid) irradiation (TMI-TMLI) is limited by the couch travel range of modern linacs, which forces to split the treatment delivery into two plans with opposite orientations: a head-first supine upper-body plan, and a feet-first supine lower-extremities plan. A specific field junction is thus needed to obtain adequate target coverage in the overlap region of the two plans. In this study, an automatic procedure was developed for field junction creation and lower-extremities plan optimization.</p> <p><strong>Methods</strong>: Ten patients treated with TMI-TMLI at our institution were selected retrospectively. The planning of the lower-extremities was performed automatically. Target volume parameters (CTV_J-V<sub>98%</sub>>98%) at the junction region and several dose statistics (D<sub>98%</sub>, D<sub>mean</sub>, and D<sub>2%</sub>) were compared between automatic and manual plans. The Modulation Complexity Score (MCS) was used to assess plan complexity.</p> <p><strong>Results</strong>: The automatic procedure required 60-90 minutes, depending on the case. All automatic plans achieved clinically acceptable dosimetric results (CTV_J-V<sub>98%</sub>>98%), with significant differences found at the junction region, where D<sub>mean </sub>and D<sub>2% </sub>increased on average by 2.4% (p<0.03) and 3.0% (p<0.02), respectively. Similar plan complexity was observed (median MCS=0.12). Since March 2022 the automatic procedure has been introduced in our clinic, reducing the TMI-TMLI simulation-to-delivery schedule by 2 days.</p> <p><strong>Conclusions</strong>: The developed procedure allowed to streamline the treatment planning of TMI-TMLI, increasing efficiency and standardization, preventing human errors, while maintaining the dosimetric plan quality and complexity of manual plans. Automated strategies can simplify the future adoption and clinical implementation of TMI-TMLI treatments in new centers.</p> <p> </p>
Dataset related to article "Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy."
<p>PURPOSE:</p> <p>This study explores the efficacy and safety of reirradiation with modern radiation therapy techniques in patients previously irradiated for prostate cancer and affected by local relapse of disease.</p> <p>METHODS AND MATERIALS:</p> <p>Patients affected by previously irradiated prostate cancer were enrolled in this reirradiation study if they had a biochemical relapse and a <sup>11</sup>C-choline positron emission tomography scan revealing the presence of a local recurrence of disease. Reirradiation consisted of a stereotactic treatment delivered by image guided radiation therapy-volumetric modulated arc therapy with flattening filter-free technology in 5 daily fractions.</p> <p>RESULTS:</p> <p>Twenty-three patients underwent reirradiation to the prostate, prostatic bed, or prostate and local recurrence. Re-treatment consisted of a median total dose of 25 Gy in 5 fractions. A biochemical response was observed in all cases. Acute toxicity was mainly genitourinary (GU) grade 1 to 2 (n = 13; 56.5%). One patient (4.3%) had grade 3 hematuria. A grade 1 GU late toxicity was registered in 4 patients (17.4%) and grade 3 in 1 patient (4.3%, urethral obstruction). Gastrointestinal toxicity was negligible. Regression analysis showed that only a short elapsed time in months from primary radiation therapy was significantly correlated with acute GU toxicity. After a median follow-up of 33 months (range, 5-58 months), the median biochemical recurrence-free survival was 19 months, and the 2-year biochemical recurrence-free survival (BRFS) was 41.7%. Median local control was 30 months; the 2-year local control rate was 58.1%.</p> <p>CONCLUSIONS:</p> <p>Reirradiation of patients with prostate cancer who underwent previous radiation therapy is a valuable option that can be safely considered to delay the beginning of hormonal treatment.</p>
Dataset related to article "Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation."
<p>OBJECTIVE:</p> <p>To assess the impact of adjuvant volumetric modulated arc therapy (VMAT) compared with three-dimensional conformal radiation therapy (3DCRT) in terms of toxicity and local control (LC) in patients with soft tissue sarcoma of the extremities.</p> <p>METHODS:</p> <p>From 2004 to 2016, 109 patients were treated, initially using 3DCRT and subsequently with VMAT. Clinical outcome was evaluated by contrast-enhanced MRI, thoracic and abdominal CT 3 months after treatments and then every 6 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events scale v. 4.3.</p> <p>RESULTS:</p> <p>Patients presented Stage III soft tissue sarcoma disease (77%), localized tumor (95%) at the lower extremity (87%), adipocytic histotype (46%). Surgical resection was performed in all patients, followed by adjuvant 3DCRT in 38, and VMAT in 71. The median total dose was 66 Gy/33 fractions (range 60-70 Gy;25-35 fractions). More successful bone sparing was recorded using VMAT (<em>p</em> < 0.001). Median follow-up was 61 months, 93 and 58 months for 3DCRT and VMAT group, respectively. The 2- and 5 year LC were 95.3±2.1%, and 87.4±3.4% for the whole cohort, 92.0±4.5%, 82.9±6.4% for 3DCRT, 97.1±2.0%, 89.6±4.1% for VMAT (<em>p</em> = 0.150). On univariate and multivariate analysis the factors recorded as conditioning LC were the status of the surgical resection margins (<em>p</em> = 0.028) and the total dose delivered (<em>p</em> = 0.013).</p> <p>CONCLUSION:</p> <p>The availability of modern radiotherapy technique permit a better conformity on the target with maximum sparing of normal tissue and acceptable side-effects. VMAT is a safe and feasible treatment with limited rate of toxicity, compared to 3DCRT. Results on LC of VMAT are encouraging.</p> <p>ADVANCES IN KNOWLEDGE:</p> <p>Soft tissue sarcoma of the extremities can benefit from the use of VMAT, with a reduction of the high dose to bones to avoid radiation osteonecrosis. An adequate total dose of at least 66 Gy and a radical surgical margin allow a good local control.</p>
Dataset related to article "Evaluation of plan complexity and dosimetric plan quality of total marrow and lymphoid irradiation using volumetric modulated arc therapy"
<p>This record contains raw data related to article "Evaluation of plan complexity and dosimetric plan quality of total marrow and lymphoid irradiation using volumetric modulated arc therapy"</p><p> Abstract</p><p>Purpose: To assess the impact of the planner's experience and optimization algorithm on the plan quality and complexity of total marrow and lymphoid irradiation (TMLI) delivered by means of volumetric modulated arc therapy (VMAT) over 2010-2022 at our institute.</p><p>Methods: Eighty-two consecutive TMLI plans were considered. Three complexity indices were computed to characterize the plans in terms of leaf gap size, irregularity of beam apertures, and modulation complexity. Dosimetric points of the target volume (D2%) and organs at risk (OAR) (Dmean) were automatically extracted to combine them with plan complexity and obtain a global quality score (GQS). The analysis was stratified based on the different optimization algorithms used over the years, including a knowledge-based (KB) model. Patient-specific quality assurance (QA) using Portal Dosimetry was performed retrospectively, and the gamma agreement index (GAI) was investigated in conjunction with plan complexity.</p><p>Results: Plan complexity significantly reduced over the years (r = -0.50, p < 0.01). Significant differences in plan complexity and plan dosimetric quality among the different algorithms were observed. Moreover, the KB model allowed to achieve significantly better dosimetric results to the OARs. The plan quality remained similar or even improved during the years and when moving to a newer algorithm, with GQS increasing from 0.019 ± 0.002 to 0.025 ± 0.003 (p < 0.01). The significant correlation between GQS and time (r = 0.33, p = 0.01) indicated that the planner's experience was relevant to improve the plan quality of TMLI plans. Significant correlations between the GAI and the complexity metrics (r = -0.71, p < 0.01) were also found.</p><p>Conclusion: Both the planner's experience and algorithm version are crucial to achieve an optimal plan quality in TMLI plans. Thus, the impact of the optimization algorithm should be carefully evaluated when a new algorithm is introduced and in system upgrades. Knowledge-based strategies can be useful to increase standardization and improve plan quality of TMLI treatments</p>
Dataset related to article "Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk"
<p>This record contains raw data related to article "Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Radiotherapy is essential in the management of head-neck cancer. During the course of radiotherapy, patients may develop significant anatomical changes. Re-planning with adaptive radiotherapy may ensure adequate dose coverage and sparing of organs at risk. We investigated the consequences of adaptive radiotherapy on head-neck cancer patients treated with volumetric-modulated arc radiation therapy compared to simulated non-adaptive plans: Materials and methods: We included in this retrospective dosimetric analysis 56 patients treated with adaptive radiotherapy. The primary aim of the study was to analyze the dosimetric differences with and without an adaptive approach for targets and organs at risk, particularly the spinal cord, parotid glands, oral cavity and larynx. The original plan (OPLAN) was compared to the adaptive plan (APLAN) and to a simulated non-adaptive dosimetric plan (DPLAN).</p><p><strong>Results: </strong>The non-adaptive DPLAN, when compared to OPLAN, showed an increased dose to all organs at risk. Spinal cord D2 increased from 27.91 (21.06-31.76) Gy to 31.39 (27.66-38.79) Gy (<i>p</i> = 0.00). V15, V30 and V45 of the DPLAN vs. the OPLAN increased by 20.6% (<i>p</i> = 0.00), 14.78% (<i>p</i> = 0.00) and 15.55% (<i>p</i> = 0.00) for right parotid; and 16.25% (<i>p</i> = 0.00), 18.7% (<i>p</i> = 0.00) and 20.19% (<i>p</i> = 0.00) for left parotid. A difference of 36.95% was observed in the oral cavity V40 (<i>p</i> = 0.00). Dose coverage was significantly reduced for both CTV (97.90% vs. 99.96%; <i>p</i> = 0.00) and PTV (94.70% vs. 98.72%; <i>p</i> = 0.00). The APLAN compared to the OPLAN had similar values for all organs at risk.</p><p><strong>Conclusions: </strong>The adaptive strategy with re-planning is able to avoid an increase in dose to organs at risk and better target coverage in head-neck cancer patients, with potential benefits in terms of side effects and disease control.</p>
Dataset related to article "Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost "
<p>This record contains raw data related to article “Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost"</p> <p><strong>Purpose: </strong> to report toxicity and cosmetic outcome with a median follow-up of 6 years of a phase II trial of hypofractionated radiotherapy with volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) for early-stage breast cancer after conservative surgery.</p> <p><strong>Materials and methods: </strong> From August 2010 to September 2014, patients requiring adjuvant radiotherapy for early-stage breast cancer were treated according to a phase I-II protocol with SIB to 40.5 and 48 Gy to the breast and the boost region, respectively, with VMAT technique. The primary endpoint evaluated the treatment feasibility regarding adherence to required dose constraints for target, heart and lungs. Acute and late toxicity, local and distant control were secondary endpoints.</p> <p><strong>Results: </strong> 450 patients were included in the trial and analysed after a median follow-up of 6 years. Acute toxicity was already presented in a previous paper. Regarding late toxicity, 93% of patients had no skin alteration at five years, while 5.3% and 1.3% did record G1 and G2 residual toxicity, respectively. Cosmetic outcome was scored good or excellent in almost all cases (97.2%), fair only in 2.3% of patients. Residual tenderness in the irradiated breast was reported by 10% of patients. Cosmesis and breast pain improved during follow-up. Two cases of G2 pneumonitis and two cases of ischemic cardiopathy were registered during follow-up. Five cases presented local recurrence in the homolateral breast, four patients had a new primary cancer in the contralateral breast, while distant metastasis developed in 7 patients.</p> <p><strong>Conclusion: </strong> After more than six years, hypofractionated VMAT with SIB for adjuvant radiotherapy in early-stage breast cancer patients remains a safe and effective approach. Mature data on skin toxicity and cosmetic outcome are encouraging. However, longer follow-up is required to evaluate local control, cardiac toxicity and secondary carcinogenesis.</p>
Dataset related to article "Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy"
<p>This record contains raw data related to article "Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy"</p> <p>PURPOSE:</p> <p>To evaluate the excess absolute risk (EAR) comparing volumetric modulated arc therapy (VMAT) and 3-dimensional (3D) conformal radiation therapy (CRT) in breast cancer radiation therapy treatment.</p> <p>METHODS AND MATERIALS:</p> <p>Two VMAT arrangements (VMAT_tang and VMAT_full, i.e. partial arcs with and without a sector of 0 Monitor Unit, respectively) and a 3D CRT (field-in-field [FinF]) plan were calculated with an accurate dose calculation algorithm, Acuros, in 20 patients presenting with early-stage breast cancer. The dose prescription was 40.05 Gy in 15 fractions. The planning aim was to maximize the dose reduction in the lungs, contralateral breast, heart, and coronary artery. EAR was estimated using different models: linear, linear-exponential, plateau, and full model, which better uses a carcinogenesis model and epidemiologic data for carcinoma induction and which accounts for cell repopulation or repair during the radiation therapy dose fractionation. EAR was computed for contralateral structures-breast and lung-as well as the ipsilateral lung. Normal tissue complication probability (NTCP) was computed to estimate the ipsilateral lung, heart, and skin toxicity, to balance with respect to second cancer induction.</p> <p>RESULTS:</p> <p>The planning objectives were fulfilled with all the planning techniques. EAR for contralateral breast carcinoma induction, estimated with the most accurate model, was 1.7, 2.4, and 8.5 (per 10,000 patients per year) with FinF, VMAT_tang, and VMAT_full, respectively. For the contralateral lung, these figures were 1.5, 1.6, and 7.3 (per 10,000 patients per year), respectively. NTCP for all the analyzed endpoints was significantly higher with FinF relative to both VMAT settings, with VMAT_full presenting the lowest toxicity risk.</p> <p>CONCLUSIONS:</p> <p>VMAT, in particular with the VMAT_tang setting, could have the same risk of second cancer induction as 3D CRT delivered with the FinF setting for the contralateral organs while reducing acute and late NTCP for the ipsilateral organs. VMAT might be considered a safe technique for breast cancer treatment for those aspects.</p>
Dataset related to article "Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ Toxicity and cosmetic outcome from a prospective series"
<p>This record contains raw data related to article "Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ Toxicity and cosmetic outcome from a prospective series"</p> <p>O</p> <p>BJECTIVE:</p> <p>Hypofractionated radiotherapy in early stage breast cancer is an effective adjuvant treatment, but there is a lack of randomized data for patients with ductal carcinoma in situ (DCIS). The aim of this study is the evaluation of skin toxicity and cosmesis, and early clinical outcome of DCIS patients enrolled in an institutional Phase II trial of hypofractionated breast irradiation.</p> <p>METHODS:</p> <p>137 DCIS patients were enrolled in the trial. All patients underwent volumetric modulated arc therapy (VMAT) to the whole breast with a total dose of 40.5 Gy in 15 fractions over 3 weeks, without tumour bed boost. Acute and late skin toxicities were recorded. Cosmetic outcomes were assessed as excellent/good or fair/poor. Early clinical outcome was reported.</p> <p>RESULTS:</p> <p>Median age was 58 y.o. (range 30-86). The median follow-up time was 22 months (range 6-45). At the end of the radiotherapy, skin toxicity was grade G1 in 56% of the patients, G2 in 15%, no patients presented G3 toxicity. In the range of 3-9 months of follow-up, the skin toxicity was G1 in 28% of patients, no G2-G3 cases; cosmetic outcome was good/excellent in 95% of patients. In the follow-up interval of 9-24 months, the skin toxicity was G1 in 12% of patients, no G2-G3 toxicity; cosmetic outcome was good/excellent in 96% of patients. After an early evaluation of clinical outcomes, 5 patients (3.6%) presented an in-breast recurrence.</p> <p>CONCLUSION:</p> <p>Hypofractionated radiotherapy using VMAT is a viable option for DCIS. A longer follow-up is needed to assess clinical outcomes and late toxicity. Advances in knowledge: The use of hypofractionated VMAT is dosimetrically feasible for treating breast DCIS.</p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.